Regeneron Pharmaceuticals Inc P/B Ratio
Data as of August 04, 2026
P/B Ratio
2.57
Stock Price
$759.24
Book Value/Share
$295.71
Sector
Biotechnology
How It's Calculated
2.57 = $759.24 ÷ $295.71
What This Means
Regeneron Pharmaceuticals Inc's P/B ratio of 2.57 is between 1 and 3. This descriptive range does not establish fair value because economically comparable P/B levels vary by sector, profitability, leverage, accounting policy, and asset composition.
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc (REGN) operates in the Biotechnology sector, specifically in Biotechnology. With a market capitalization of about $79.94B, it ranks as a large-cap stock — a major established company.
Shares recently traded near $759.24, within a 52-week range of $541.00 to $821.11 (-7.5% from the high, +40.3% from the low). Beta of 0.19 indicates relatively lower volatility versus the market.
Trailing profit margin is about 29.6%, signaling a strong profit margin relative to many peers.
Understanding This Metric
The price-to-book ratio compares market price to net asset value per share. For Regeneron Pharmaceuticals Inc, P/B is especially useful when earnings are volatile or temporarily depressed. In Biotechnology, asset-heavy business models often anchor closer to book value, while asset-light models may trade far above book.
Sector Comparison
Among Biotechnology names on our S&P 100 coverage, Regeneron Pharmaceuticals Inc's P/B ratio of 2.57 can be compared with peers such as AMGN (23.58), GILD (7.17). Sector context helps interpretation, but each company's growth profile and balance sheet differ — use multiple metrics before drawing conclusions. View all Biotechnology stocks.
Key Takeaways
- REGN is grouped in the Biotechnology sector for peer comparisons.
- Recent beta of 0.19 suggests lower-than-market price sensitivity.
- Trailing profit margin of 29.6% provides context for how much earnings support the headline multiple.
Related Tools & Guides
Explore calculators and guides connected to this metric, or view all metrics for REGN.
Learn the full workflow
Compare PE with PB, PEG, EV/EBITDA, and market cap in one structured path.
Open the Stock Valuation hub →Other REGN Metrics
Frequently Asked Questions
What does REGN's price-to-book ratio indicate?
P/B compares share price to book value per share. Regeneron Pharmaceuticals Inc's P/B of 2.57 reflects how the market prices net assets — especially relevant for asset-heavy Biotechnology business models.
Is 2.57 above or below book value?
A P/B above 1.0 (2.57) means the market values REGN above accounting book value — often due to brands, growth, or intangible assets.
How does P/B compare within Biotechnology?
Peer P/B levels in Biotechnology (e.g. AMGN (23.58), GILD (7.17)) provide context; asset-light vs asset-heavy models differ materially.
Calculate the p/b ratio for any stock with our free calculator.
Open P/B Ratio Calculator →